02:00 PM EDT, 06/17/2024 (MT Newswires) -- Health care stocks were declining Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%.

The iShares Biotechnology ETF (IBB) fell 0.5%.

In corporate news, Mirum Pharmaceuticals ( MIRM ) shares jumped 22% after reporting positive interim results for its volixibat drug candidate during phase 2b testing in patients with primary biliary cholangitis and primary sclerosing cholangitis.

BioNTech (BNTX) sank 4.8% after the firm said its partner MediLink Therapeutics has informed the company that the US Food and Drug Administration has placed a partial hold on enrolling new patients in the US in its phase 1 trial assessing its product candidate for advanced cancers due to safety concerns.

Mustang Bio ( MBIO ) soared 310% after updated data from a phase 1/2 trial of MB-106 indicated a 90% overall response rate in Waldenstrom macroglobulinemia blood cancer patients previously treated with Bruton's tyrosine kinase inhibitors.